Long-term outcomes in <i>FLT3</i>-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitorNicholas J. Short, Naval Daver, Sanam Loghavi et al.|Haematologica|2025Cited by 2
A comprehensive analysis of PCR for BCR::ABL1 and next-generation sequencing (NGS)-based measurable residual disease (MRD) with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): Prevalence, association with transcript type, and clinical outcomesManuel Maroun, Nicholas J. Short, Sanam Loghavi et al.|Blood|2025Cited by 2
Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated Acute Myeloid LeukemiaRoberta S. Azevedo, Nicholas J. Short, Naval Daver et al.|Blood|2025Cited by 2